Takeda unveils secondary endpoint data from Phase III PsO pill trials
The key secondary endpoints found the PsO pill to be beneficial in high-impact areas, including the scalp, palms, and soles.
Therapy Area
Veradermics stock jumps again on female hair loss drug win
Loneliness interventions do not have strong sustained effects on memory function
AAIC26: Biogen stock drops after unveiling tau-targeting ASO data
Alkermes releases nine-month data as OX2R race heats up
Roche culls development of two Huntington’s disease programmes
Satellos’ oral DMD drug improves arm movement after six months in Phase II
Addressing sexual minority gaps in cervical and breast cancer screening
